GAM Holding AG bought a new position in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 95,000 shares of the biotechnology company’s stock, valued at approximately $2,062,000. GAM Holding AG owned 0.23% of Albany Molecular Research as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Royce & Associates LP increased its position in Albany Molecular Research by 17.6% in the first quarter. Royce & Associates LP now owns 1,518,276 shares of the biotechnology company’s stock worth $21,301,000 after buying an additional 227,365 shares during the period. Vanguard Group Inc. increased its position in Albany Molecular Research by 6.4% in the first quarter. Vanguard Group Inc. now owns 1,320,055 shares of the biotechnology company’s stock worth $18,521,000 after buying an additional 79,155 shares during the period. Chicago Capital Management LLC bought a new position in Albany Molecular Research during the second quarter worth approximately $21,417,000. Walthausen & Co. LLC increased its position in Albany Molecular Research by 16.0% in the first quarter. Walthausen & Co. LLC now owns 831,285 shares of the biotechnology company’s stock worth $11,663,000 after buying an additional 114,430 shares during the period. Finally, AMI Asset Management Corp increased its position in Albany Molecular Research by 4.3% in the second quarter. AMI Asset Management Corp now owns 735,876 shares of the biotechnology company’s stock worth $15,969,000 after buying an additional 30,383 shares during the period. 72.10% of the stock is currently owned by hedge funds and other institutional investors.

Albany Molecular Research, Inc. (AMRI) opened at 21.73 on Tuesday. The company has a 50 day moving average of $21.71 and a 200-day moving average of $18.32. The stock’s market capitalization is $905.40 million. Albany Molecular Research, Inc. has a 52-week low of $13.01 and a 52-week high of $22.17.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/gam-holding-ag-buys-new-stake-in-albany-molecular-research-inc-amri/1529214.html.

A number of research analysts recently commented on AMRI shares. First Analysis downgraded shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research report on Monday, June 12th. William Blair reaffirmed an “outperform” rating on shares of Albany Molecular Research in a research report on Tuesday, May 23rd. BidaskClub raised shares of Albany Molecular Research from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Morgan Stanley downgraded shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 target price on the stock. in a research report on Thursday, May 11th. They noted that the move was a valuation call. Finally, J P Morgan Chase & Co downgraded shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research report on Thursday, June 8th. Five analysts have rated the stock with a hold rating, The company presently has an average rating of “Hold” and a consensus target price of $18.00.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.